Ascendis Pharma A/S
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
公司地址 Tuborg Boulevard 12, Hellerup, DNK, 2900
電話號碼 +45 70222244
傳真號碼 --
公司網頁 https://www.ascendispharma.com
員工數量 1189
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Michael Wolff Jensen, L.L.M. Executive Vice President and Chief Legal Officer -- 11/02/2026
Mr. Jan Moller Mikkelsen President, Chief Executive Officer and Director -- 11/02/2026
Ms. Lotte Sonderbjerg Executive Vice President and Chief Administrative Officer -- 11/02/2026
Mr. Flemming Steen Jensen Executive Vice President, Product Supply and Quality -- 11/02/2026
Dr. Kennett Sprogoe, PhD Executive Vice President and Head of Innovation and Research -- 11/02/2026
Mr. Scott T Smith Executive Vice President and Chief Financial Officer -- 11/02/2026
Dr. Stina Singel, M.D.,PhD Executive Vice President and Head of Clinical Development, Oncology -- 11/02/2026
Ms. Aimee Shu Executive Vice President and Chief Medical Officer -- 11/02/2026
Mr. Jay Donovan Wu Executive Vice President and U.S. President -- 11/02/2026
Mr. Mads Bodenhoff Senior Vice President, Head of Finance and Principal Accounting Officer -- 11/02/2026
Dr. Jethro Ekuta, D.V.M.,PhD Chief Regulatory and Safety Officer -- 11/02/2026
Ms. Sherrie Glass, M.P.A. Chief Business Officer -- 11/02/2026
 
董事會成員
董事會 職務 更新日期
Dr. Albert Cha, M.D.,PhD Chairman of the Board 11/02/2026
Mr. Jan Moller Mikkelsen President, Chief Executive Officer and Director 11/02/2026
Ms. Lisa Bright Independent Director 11/02/2026
Mr. William Carl Fairey, Jr Independent Director 11/02/2026
Mr. Lars Holtug Independent Director 11/02/2026
Ms. Siham Imani Independent Director 11/02/2026
 
所屬ETF (更新日期: 19/09/2026 02:53)
代號 名稱 佔比% ▼ 持有日期
FPXEFirst Trust IPOX Europe Equity Opps ETF0.0001%30/08/2026
TNXTT. Rowe Price Innovation Leaders ETF0.0001%29/08/2026
QQHGInvesco QQQ Hedged Advantage ETF0.0001%31/08/2026
MNZLManzil Russell Halal USA Broad MarketETF0.0001%31/08/2026
ONEOStt Strt® SPDR® Russell 1000 Momt FocETF0.00005%31/08/2026
IBFRInnovator International Dev Mgd 10BfrETF0.00005%31/08/2026
REMCColumbia Research Enhanced Mid Cap ETF0.00004%29/08/2026
REVSColumbia Research Enhanced Value ETF0.00004%29/08/2026
WDAIPacer S&P World 3AI TOP 300 ETF0.00002%31/08/2026
RECIColumbia Research Enhanced Cor PrmIncETF0.00001%29/08/2026
TACUT. Rowe Price Active Core U.S. Eq ETF0.000001%29/08/2026
AAUAAlpha Architect US Equity 3 ETF<0.000001%08/07/2026
APIEActivePassive International Equity ETF<0.000001%21/05/2026
BRESBurney U.S. Equity Select ETF<0.000001%15/07/2026
CGOCalamos Global Total Return<0.000001%30/06/2026
CHWCalamos Global Dynamic Income<0.000001%30/06/2026
FFTYCapForce IBD® 50 ETF<0.000001%20/07/2026
FTLSFirst Trust Long/Short Equity ETF<0.000001%04/06/2026
HRTSTema Heart & Health ETF<0.000001%24/06/2026
IALTiShares Systematic Alternatives Actv ETF<0.000001%31/07/2026
  1    2    3   4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.